It has been reported that Cyramza® (ramucirumab) has met its primary endpoint of overall survival, as well as its secondary goal of progression-free survival in late-stage liver cancer study.
The trial, termed REACH-2 involved 292 randomized patients with hepatocellular carcinoma who were intolerant to, or that had disease progression while on or following treatment with Nexavar® (sorafenib) and had high levels of the glycoprotein alpha-fetoprotein to receive Cyramza or placebo, both in combination with best supportive care.
“Advanced liver cancer is an aggressive disease that has a poor prognosis – and for those that have elevated glycoprotein alpha-fetoprotein levels, the prognosis is even more dismal. For this reason, Lilly is encouraged by the results of REACH-2 and the potential for Cyramza to benefit patients in this setting.” Levi Garraway, senior vice president of global development and medical affairs at Lilly Oncology (US) explained.
The design of the REACH-2 trial is based on the findings from the Phase III REACH study, in this study Cyramza has failed to significantly improve survival in the entire patient cohort, while key secondary endpoints were met in a pre-specified subgroup of patients with high glycoprotein alpha-fetoprotein levels.
Initially, Cyramza was approved in 2014 in the US for use in certain patients with unresectable or metastatic gastric cancer or gastroesophageal junction adenocarcinoma, following this it gained clearance for use in combination with paclitaxel. It is also authorized in the US for patients with metastatic non-small-cell lung cancer.